Triple Celebrations | Grand Opening of YHLO Qide Tower
On September 10, Shenzhen YHLO Biotech Co., Ltd. officially inaugurated its second industrial park, Qide Tower, marking a significant milestone in YHLO’s development. In his opening remarks, Chairman of YHLO, Mr. Hu Kunhui, emphasized that this new facility not only symbolizes YHLO’s strength and ingenuity but also signifies the company’s deep commitment to exploring the future of medical technology.
The event also featured the unveiling of two collaborative projects: the Peking University-YHLO Joint Laboratory for Molecular Diagnosis of Infectious Diseases and the Cardiovascular Disease Diagnostics Research Center. Additionally, YHLO introduced its latest innovation, the iTLA Max Laboratory Automation System.
The event was attended by distinguished guests, including Academician Zhuang Hui from the Chinese Academy of Engineering, professor of Pathogenic Biology and Infectious Disease at Peking University Health Science Center; Academician Gu Dongfeng, preventive cardiologist and acting vice president of the Southern University of Science and Technology; Academician Zheng Zhongxuan from the Canadian Academy of Health Sciences and founding dean of the Faculty of Medicine at The Chinese University of Hong Kong (Shenzhen); Mr. Liu Wang, secretary of the Party Committee of Hunan University of Technology; Mr. Zhou Zhou, director of the Laboratory Diagnostic Center at the National Center for Cardiovascular Diseases/Fuwai Hospital of the Chinese Academy of Medical Sciences; Mr. Song Haibo, vice president of the National Health Industry Enterprise Management Association, president of the Medical Testing Industry Division, vice president of the Shanghai Institute of Experimental Medicine, and founder of CACLP; Mr. Wang Hualiang, chairman of the Laboratory Medicine Division of the National Health Industry Enterprise Management Association and director of the Shanghai Institute of Experimental Medicine; Mr. Li Xuejin, associate vice president and director of the Research Department at The Chinese University of Hong Kong (Shenzhen); Mr. Ito Hiroshi, president of Japan MBL Corporation; and Mr. Chen Xiaozi, district councilor of Tsuen Wan, Hong Kong. In addition, chairman Hu Kunhui, along with the entire senior management team, were also present to witness this historic moment.
At 9:00 AM, amid warm applause, the opening ceremony of Qide Tower officially began. Medical industry experts, partners, and distinguished guests from all walks of life gathered to celebrate this landmark achievement.
The Qide Tower project is located at the intersection of New Energy Road One and New Energy Road Five in the Baolong subdistrict of Longgang District, Shenzhen. With a total investment of 608 million yuan and a construction area of 109,000 square meters, the facility integrates offices, research laboratories, production workshops, logistics, dining facilities, and dormitories into a multifunctional comprehensive building.
In line with the overall planning of Longgang District’s high-tech industrial park, Qide Tower incorporates independent living and production areas separated by landscaped divisions, creating a versatile space. This high-standard, high-quality industrial park is designed to support YHLO’s growth and innovation.
Qide Tower is YHLO’s second industrial park, located just across the road from YHLO’s Biotech Tower, which covers 10,000 square meters. Together, these facilities will provide YHLO with more than 160,000 square meters of office and production space, supporting its growth in scale and capacity while laying a solid foundation for future innovation.
In his speech, Chairman Hu Kunhui expressed his gratitude to the attending guests and emphasized YHLO’s long-term development strategy for the next decade. He highlighted that while YHLO will continue to focus on its current platforms and diagnostic fields, it will also expand into future areas such as microfluidics and gene sequencing. He emphasized that the opening of Qide Tower presents an opportunity to bring together greater innovation and strengthen the integration of industry, academia, and research. YHLO remains committed to driving industry progress and contributing to the national healthcare system, aiming to become the world's leading in vitro diagnostics company within the next decade.
Academician Zhuang Hui from Peking University extended his heartfelt congratulations during the ceremony. He noted the significant achievements of the long-standing partnership between Peking University and YHLO, particularly in the joint laboratory, which is expected to bring breakthroughs in the diagnosis of liver diseases. He praised YHLO’s sense of social responsibility and reiterated the joint commitment to advancing technological innovation in liver disease diagnostics, contributing to the "Healthy China 2030" strategy.
The official opening of YHLO’s new headquarters symbolizes a leap in comprehensive strength, while the establishment of the joint laboratory with renowned academicians represents the company's pursuit of technological innovation. Following the inauguration, the unveiling of the Peking University-YHLO Joint Laboratory for Molecular Diagnosis of Infectious Diseases took place in the presence of esteemed guests.
The Peking University-YHLO Joint Laboratory, established in October 2021, aims to create world-class diagnostic technologies for viral infectious diseases. Over the past three years, the joint laboratory has made significant progress, including the development of diagnostic reagents for Hepatitis D antibody and nucleic acid testing, as well as large, medium, and small Hepatitis B virus surface antigen detection kits. The Hepatitis D virus antibody and nucleic acid test kits are expected to be officially launched next year.
Building on the success of the first phase of collaboration, Academician Zhuang Hui unveiled the second phase of the joint laboratory at the event. Chairman Hu Kunhui and Professor Shen Tao of Peking University delivered enthusiastic speeches, signaling a new chapter in industry-academia-research collaboration between YHLO and Peking University, aimed at advancing China’s healthcare and driving the transformation of cutting-edge technology.
On this milestone day, YHLO also officially launched its independently developed iTLA Max Laboratory Automation System. Chairman Hu emphasized that this innovative solution integrates the advantages of mainstream automation lines in the market and represents a leap in product performance. By combining artificial intelligence, visual recognition, and other cutting-edge technologies, iTLA Max achieves comprehensive intelligent integration across pre-analysis, analysis, and post-analysis processes, significantly improving the efficiency of clinical laboratory testing and operational management.
Song Haibo, president of the Medical Testing Industry Division of the National Health Industry Enterprise Management Association, highly praised YHLO’s spirit of innovation, acknowledging the company’s systematic product offerings and continuous advancements in research and development. He noted that the opening of Qide Tower, the establishment of the joint laboratory, and the launch of iTLA Max would propel YHLO toward becoming a leading global force in the in vitro diagnostics industry.
The launch event concluded with a detailed introduction of the iTLA Max product by Mr. Hu Zhiheng, YHLO’s Deputy General Manager of Sales, highlighting its technical innovations and market potential.
With the successful inauguration of Qide Tower, YHLO embarks on a new journey of technological innovation and industrial upgrading in the field of in vitro diagnostics. Leveraging its new facilities and joint laboratories, YHLO will continue to focus on research, development, and innovation, delivering high-quality products and services that meet market demands, while contributing to industry progress and global health.
Attachments:
MORE NEWS
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
